Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547066 · ClinicalTrials.gov registry record · Phase 1
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00547066 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 48 participants.
The verdict
NCT00547066, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
Interventions
- BIOLOGICAL veltuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547066
The ClinicalTrials.gov registry entry for NCT00547066 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which veltuzumab is the first listed.
NCT00547066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547066 about?
NCT00547066 is a clinical study titled "Study of Veltuzumab (hA20) at Different Doses in Patients With ITP". This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
What is the current status of trial NCT00547066?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2007-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00547066?
The interventions under investigation include: veltuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00547066?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.